Page 215 - 2021_12-Haematologica-web

Letters to the Editor
instead of dexamethasone and the omission of high-dose methotrexate, both part of the B-NHL therapy.
In conclusion, our prospective data confirmed DA-EPOCH-R as effective treatment for children and adolescents with PMBCL with only one patient receiving consolidation radiotherapy. Further trials on PMBCL should address the risk of CNS relapse and identify prog- nostic markers. Low patient numbers in this orphan dis- ease call for collaborative, international trials including patients of the whole age spectrum.
Fabian Knörr,1 Martin Zimmermann,2 Andishe Attarbaschi,3 Edita Kabíčková,4 Britta Maecker-Kolhoff,2 Stephanie Ruf,5 Ingrid Kühnle,6 Martin Ebinger,7 Anne-Kathrin Garthe,8
Ingrid Simonitsch-Klupp,9 Ilske Oschlies,10 Wolfram Klapper,10 Birgit Burkhardt8 and Wilhelm Woessmann1
1University Medical Center Hamburg-Eppendorf, Pediatric
2
Hematology and Oncology, Hamburg, Germany; Hannover Medical
School, Clinic for Pediatric Hematology and Oncology, Hannover, Germany; 3St. Anna Children’s Hospital, Medical University of Vienna, Department of Pediatric Hematology and Oncology, Vienna, Austria; 4Charles University and University Hospital Motol, Department of Pediatric Hematology and Oncology, Prague, Czech Republic; 5Justus-Liebig-University of Gießen, Pediatric Hematology and Oncology, Gießen, Germany; 6University Medical Center Göttingen, Division of Pediatric Hematology and Oncology, Göttingen, Germany; 7Children's University Hospital Tübingen, Department of General Pediatrics and Pediatric Hematology/Oncology, Tübingen, Germany; 8University-Hospital of Münster, Pediatric Hematology and Oncology, Münster, Germany; 9Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; 10University Hospital Schleswig- Holstein, Campus Kiel, Institute of Pathology, Hematopathology Section and Lymph Node Registry, Kiel, Germany
Correspondence:
WILHELM WOESSMANN- w.woessmann@uke.de doi:10.3324/haematol.2021.278971
Received: April 28, 2021.
Accepted: August 27, 2021.
Pre-published: September 9, 2021.
Disclosures: AA received honoraria from Jazz Pharmaceuticals, Amgen, MSD, Novartis, travel grants from Jazz Pharmaceuticals, and has consulting or advisory roles for Jazz Pharmaceuticals, Amgen, MSD, Gilead and Novartis; ME has received travel grants and honoraria from Amgen, MSD and Jazz Pharmaceuticals;
WK received research funding by Roche, Amgen, Regeneron and Takeda. The remaining authors have no conflicts of interest to disclose.
Contributions: WW, BB, AA, EK designed and supervised treatment in the NHL-BFM registry 2012. WW and FK designed the concept and the analysis; FK, MZ, SR and AG collected and assembled data; AA, EK, BMK, IK, ME provided patient data; ISK, IO, WK performed reference pathology review; FK and WW wrote the first draft
of the manuscript; MZ and FK carried out the statistical analysis; WW and BB supervised the analysis; all authors critically revised the manuscript; all authors gave their approval of the final manuscript.
Acknowledgments: we thank all patients and their families for participating in the studies. We thank our colleagues in the hospitals and reference institutions, who contributed to this study, for their care for the children and families, and the supplied data.
References
1. Gerrard M, Waxman IM, Sposto R, et al. Outcome and pathologic clas- sification of children and adolescents with mediastinal large B-cell lym- phoma treated with FAB/LMB96 mature B-NHL therapy. Blood. 2013;121(2):278-285.
2. Seidemann K, Tiemann M, Lauterbach I, et al. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin- Frankfurt-Münster Group. J Clin Oncol. 2003;21(9):1782-1789.
3. Cairo MS, Sposto R, Gerrard M, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and ado- lescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012;30(4):387-393.
4. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-ritux- imab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408-1416.
5. Woessmann W, Lisfeld J, Burkhardt B. Therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;369(3):282-284.
6. Giulino-Roth L, O'Donohue T, Chen Z, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose- adjusted EPOCH-R. Br J Haematol. 2017;179(5):739-747.
7. Burke GAA, Gross TG, Pillon M, et al. Results of Inter-B-NHL Ritux 2010 - phase II study of DA-EPOCH-R for children and adolescents with primary mediastinal large B-cell lymphoma (PMLBL) on behalf of European Intergroup for Childhood Non Hodgkin's Lymphoma (EIC- NHL) and Children's Oncology Group (COG). Blood. 2017;130(Suppl 1):S4124.
8.Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of chil- dren and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105(3):948-958.
9. Gray RJ. A Class of K-Sample Tests for comparing the cumulative inci- dence of a competing Risk. Ann Stat. 1988;16(3):1141-1154.
10. Shah NN, Szabo A, Huntington SF, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lym- phoma: a multi-centre analysis. Br J Haematol. 2018;180(4):534-544.
11. Melani C, Advani R, Roschewski M, et al. End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose- adjusted EPOCH-R: a paradigm shift in clinical decision making. Haematologica. 2018;103(8):1337-1344.
12. Rieger M, Österborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rit- uximab: results of the Mabthera International Trial Group study. Ann Oncol. 2011;22(3):664-670.
13. Martelli M, Zucca E, Botto B, et al. Impact of different induction regi- mens on the outcome of primary mediastinal B cell lymphoma in the Prospective Ielsg 37 Trial. Hematol Oncol. 2021;39(S2):S90-92.
14. Pillon M, Carraro E, Mussolin L, et al. Primary mediastinal large B-cell lymphoma: outcome of a series of pediatric patients treated with high- dose methotrexate and cytarabine plus anti-CD20. Pediatr Blood Cancer. 2018;65(2).
15. Murphy SB. Classification, staging and end results of treatment of child- hood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7(3):332-339.
haematologica | 2021; 106(12)
3235